Biotechnology News and Research

RSS

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists at Scripps Institution of Oceanography at UC San Diego and their colleagues at Creighton University have deciphered the highly unusual molecular structure of a naturally produced, ocean-based compound that is giving new understanding of the function of mammalian nerve cells.

29 Aug 2009

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Geneuity Clinical Research Services announces the recent validation and use in clinical trials of two human biomarker assays that play a key role in the early detection of kidney damage.

29 Aug 2009

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease. They have been studying the impacts of nerve growth factors in the treatment of PD, and their latest results show that a certain growth factor can be used to halt the progress of damage brought on by a nerve poison and possibly even restore the function of damaged cells.

28 Aug 2009

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

28 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Researches report new results that may help in better treament for patients with Parkinson's disease

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

ASHG 2009 Annual Meeting to discuss the cutting-edge developments in human genetics and genomics research

The world's top scientists and clinicians in the human genetics field will gather in Honolulu, Hawaii to present their latest research findings at the 59th Annual Meeting of the American Society of Human Genetics, from Tuesday, October 20, through Saturday, October 24, 2009, at the Hawaii Convention Center.

28 Aug 2009

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.

28 Aug 2009

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

28 Aug 2009

Fast Forward selects IntraLinks to support its funding effort

IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.

28 Aug 2009

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.

28 Aug 2009

Scientists discover the vulnerability of old people to cancer and skin infections

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have discovered why older people may be so vulnerable to cancer and infections in the skin. The team from UCL has shown in human volunteers that defective immunity in the skin is caused by an inability to mobilise essential defences that would otherwise recognise threats and clear them before irreparable damage is done.

28 Aug 2009

Biotechnology Industry Organization mourns the death of Ted Kennedy

BIO joins the nation in mourning the loss of Senator Ted Kennedy. A dedicated public servant for more than four decades, Senator Kennedy was well-known for his leadership on health care issues in the Senate.

27 Aug 2009

Viral Genetics cautions investors and the public to rely only on its own releases and disclosures

Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on Today's Financial News entitled "TFN Reader Grapevine: There's Something About Viral Genetics, Inc. (VRAL)," on August 25.

27 Aug 2009

Researchers reveal that nonextractable polyphenols in fruits are a major part of bioactive compounds

An international team of scientists has found that the polyphenol content of fruits has been underestimated. Polyphenol content in fruits usually refers to extractable polyphenols, but a Spanish scientist working at the Institute of Food Research in Norwich analysed apple, peach and nectarine. She found that nonextractable polyphenol content is up to five times higher than extractable compounds. This work has been published in the Journal of Agricultural and Food Chemistry.

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

California Bioscience Business Roundtable event hosted at the Quadrus Conference Center

Today a group of national and California-based partners hosted the California Bioscience Business Roundtable (BBR) event at the Quadrus Conference Center in Menlo Park. The event also featured Sam Youngman, the White Correspondent for The Hill newspaper, who provided a reporter's front row perspective on the unfolding health reform debate in Washington, D.C.

27 Aug 2009

Microvi Biotech raises funds for product development

Microvi Biotech Inc., a leader in clean and waste-free water treatment technologies, today announced the completion of its first round of equity financing. The company plans to use the proceeds from the Series A financing to expand product development, grow the company’s team, enhance the company R&D pipeline, and pave the way for the launch and commercialization of new, one-of-a-kind water technologies. The specific terms of the financing were not disclosed.

27 Aug 2009

Biotechnology News and Research

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

New compound discovered by Scripps scientists offers a novel template for drug development

Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Researches report new results that may help in better treament for patients with Parkinson's disease

Thrombogenics issues business update and half year results

ASHG 2009 Annual Meeting to discuss the cutting-edge developments in human genetics and genomics research

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Fast Forward selects IntraLinks to support its funding effort

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Scientists discover the vulnerability of old people to cancer and skin infections

Biotechnology Industry Organization mourns the death of Ted Kennedy

Viral Genetics cautions investors and the public to rely only on its own releases and disclosures

Researchers reveal that nonextractable polyphenols in fruits are a major part of bioactive compounds

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

California Bioscience Business Roundtable event hosted at the Quadrus Conference Center

Microvi Biotech raises funds for product development

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News